Thabut D
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.
-
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.
-
Non-invasive diagnosis and follow-up of portal hypertension.
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
-
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
-
Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.
-
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
-
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
-
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
-
FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.
-
Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.
-
Noninvasive assessment of portal hypertension in patients with cirrhosis.
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
-
ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.
-
Applicability and variability of liver stiffness measurements according to probe position.
-
Liver biopsy: the best standard...when everything else fails.
-
The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
-
Assessment of liver fibrosis: noninvasive means.
-
Biomarkers of liver fibrosis.
-
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.
-
FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence.
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication
-
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.
-
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
-
Relationship between the Fibrotest and portal hypertension in patients with liver disease.
-
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication
-
Diagnostic value of FibroTest with normal serum aminotransferases.
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
-
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
-
Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.
-
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.
-
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
-
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
-
Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).
-
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.
-
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.
-
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.
-
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
-
Noninvasive prediction of fibrosis in patients with chronic hepatitis C.
-
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.